Scholarlink

Background <p>Antibiotics are currently the primary treatment of <i>Clostridioides difficile</i> (<i>C. difficile</i>) infection. Yet, due to rapid development of resistance and high recurrences rates, there is an unmet need for new antimicrobials for <i>C. difficile</i> infections. This study assessed the in vitro susceptibility of clinical isolates from Israel to two recently developed antibiotics, ridinilazole (RDZ) and ibezapolstat (IBZ), and to standard-of-care antibiotics.</p> Methods <p><i>C. difficile</i> isolates (<i>n</i> = 313) recovered from patients at both community and hospital medical centers across Israel, were typed to different sequence types (ST) by multi-locus sequencing typing (MLST). Susceptibility to metronidazole (MTZ) and vancomycin (VAN) was determined using the gradient strip test (Etest). Susceptibility to fidaxomicin (FDX), RDZ and IBZ was determined by agar dilution.</p> Results <p>ST42 (39; 12.5%) and ST2 (36; 11.5%) were the most prevalent STs. Resistance to MTZ and VAN was low (2.2%, 1.6%, respectively), while 23 (7.35%) isolates were FDX-resistant. RDZ MIC ranged between 0.06 and 0.5&#xa0;mg/L, and MIC<sub>50/90</sub> was 0.25/0.5&#xa0;mg/L. IBZ had an MIC<sub>50/90</sub> of 4&#xa0;mg/L. No significant differences were noted in IBZ MIC of different strains.</p> Conclusions <p>RDZ and IBZ demonstrated potent in vitro activity against 313 <i>C. difficile</i> isolates belonging to different STs. These two antimicrobials may serve as effective agents for <i>C. difficile</i> infection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat,

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月31日

查看全文
  • Orna Schwartz,
  • Maya Azrad,
  • Avi Peretz

摘要

Background

Antibiotics are currently the primary treatment of Clostridioides difficile (C. difficile) infection. Yet, due to rapid development of resistance and high recurrences rates, there is an unmet need for new antimicrobials for C. difficile infections. This study assessed the in vitro susceptibility of clinical isolates from Israel to two recently developed antibiotics, ridinilazole (RDZ) and ibezapolstat (IBZ), and to standard-of-care antibiotics.

Methods

C. difficile isolates (n = 313) recovered from patients at both community and hospital medical centers across Israel, were typed to different sequence types (ST) by multi-locus sequencing typing (MLST). Susceptibility to metronidazole (MTZ) and vancomycin (VAN) was determined using the gradient strip test (Etest). Susceptibility to fidaxomicin (FDX), RDZ and IBZ was determined by agar dilution.

Results

ST42 (39; 12.5%) and ST2 (36; 11.5%) were the most prevalent STs. Resistance to MTZ and VAN was low (2.2%, 1.6%, respectively), while 23 (7.35%) isolates were FDX-resistant. RDZ MIC ranged between 0.06 and 0.5 mg/L, and MIC50/90 was 0.25/0.5 mg/L. IBZ had an MIC50/90 of 4 mg/L. No significant differences were noted in IBZ MIC of different strains.

Conclusions

RDZ and IBZ demonstrated potent in vitro activity against 313 C. difficile isolates belonging to different STs. These two antimicrobials may serve as effective agents for C. difficile infection.